Global collaboration focusing on novel biologics in Oncology

Cambridge, MA, Rotterdam, NL, Shanghai, CN July 10, 2019

Yinouke and Harbour BioMed today announced entering into a long-term partnership to discover, develop and commercialize first-in-class biologics for multiple targets in oncology

The collaboration will complement Harbour BioMed’s discovery capabilities, including its transgenic mouse platforms for generating fully human antibodies, with Yinuoke’s discovery capabilities and profound insights in cancer and cancer related disease.

"We are delighted to partner with Harbour BioMed to accelerate the development of effective treatments for cancer patients who have no available therapeutic options. I believe this will be a historical collaboration which will lead to groundbreaking cancer therapeutics" said Dr.Lingbing Zhang, Founder and CEO of Yinuoke.

"Both Harbour BioMed and Yinuoke are committed to bringing novel treatments for cancer patients across all stages. This specific partnership further exemplifies HBM’s philosophy to co-discover therapeutic solutions and accelerate their advancement through development and commercialization to address global patient needs." said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed. 

Under the terms of the agreement, the two companies will invest in discovering multiple first-in-class monoclonal antibodies up to IND ready stage. Thereafter, Yinuoke and Harbour BioMed will be responsible for clinical development and commercialization of the therapeutic candidates, emerging from the collaboration, in their respective territories.

About Yinuoke

Yinuoke is a biotech company founded with the mission to develop groundbreaking therapeutics for cancer patients. Our initial R&D program is focused on identifying the underlying mechanisms which cause the rapid health deterioration and death of late stage cancer patients. Our deep understanding of cancer biology has resulted in first-in-class product candidates that will provide novel treatments for patients with no available options. 

About Harbour BioMed

 
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.

 
The Company’s proprietary antibody technology platforms Harbour Mice^® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE^®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice^® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies. 

For further information, please refer to www.harbourbiomed.com

Contact:

Richard YU

BD@harbourbiomed.com